<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acquired hypopigmentation disorders other than vitiligo</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acquired hypopigmentation disorders other than vitiligo</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acquired hypopigmentation disorders other than vitiligo</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mi Ryung Roh, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sang Ho Oh, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hensin Tsao, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3527812372"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The color of human skin is mainly determined by the two types of melanin, the black-brown eumelanin and the yellow-red pheomelanin. Other significant contributors include the capillary blood flow, chromophores such as carotene or lycopene, and the collagen content of the dermis. Altered skin pigmentation can result from increased or decreased melanin, abnormal melanin distribution, decreased hemoglobin, or deposition of exogenous substances [<a href="#rid1">1</a>].</p><p>"Hypopigmentation" is a general term that refers to any form of decreased or absent skin pigmentation caused by melanin, hemoglobin, or any other reasons. "Hypomelanosis" more specifically refers to a reduction of epidermal melanin. Hypopigmentation disorders may be congenital or acquired, diffuse (generalized) or localized, and may occur in isolation or be associated with a wide range of congenital or acquired disorders [<a href="#rid2">2-4</a>].</p><p>This topic will review the acquired hypopigmentation disorders other than vitiligo. Vitiligo is discussed separately. Congenital hypopigmentation disorders are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/105109.html" rel="external">"Vitiligo: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/106619.html" rel="external">"Vitiligo: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15469.html" rel="external">"Oculocutaneous albinism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/97404.html" rel="external">"Pigmentary mosaicism (hypomelanosis of Ito)"</a>.)</p><p></p><p class="headingAnchor" id="H3523881837"><span class="h1">DIAGNOSTIC APPROACH</span><span class="headingEndMark"> — </span>The diagnosis of hypopigmentation disorders is in many cases made on clinical grounds, based upon a detailed medical history and physical examination [<a href="#rid5">5</a>]. The lesion morphology, color (hypopigmented or depigmented), distribution, and pattern are important clues to the diagnosis. However, examination with a Wood's light, a skin biopsy, and additional laboratory tests may be required if the clinical diagnosis is uncertain. The differential diagnosis of hypopigmentation disorders is illustrated in the algorithm  (<a class="graphic graphic_algorithm graphicRef108830" href="/d/graphic/108830.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H3365847756"><span class="h2">Patient evaluation</span><span class="headingEndMark"> — </span>The initial patient evaluation involves a detailed family and personal history and a complete physical examination, which should include a careful search for additional cutaneous and extracutaneous signs and symptoms.</p><p>The following questions may be useful for the evaluation of patients presenting with hypopigmentation disorders  (<a class="graphic graphic_algorithm graphicRef108830" href="/d/graphic/108830.html" rel="external">algorithm 1</a>) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Is the disorder congenital or acquired?</p><p class="bulletIndent1"><span class="glyph">●</span>Is the hypopigmentation localized or diffuse?</p><p class="bulletIndent1"><span class="glyph">●</span>Are lesions well circumscribed or ill defined?</p><p class="bulletIndent1"><span class="glyph">●</span>Does the hypopigmentation have a pattern (eg, linear, reticular)?</p><p class="bulletIndent1"><span class="glyph">●</span>Is the hypopigmentation associated with prior inflammation or cutaneous injury?</p><p class="bulletIndent1"><span class="glyph">●</span>Are the lesions stable, progressing, or regressing?</p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient have concomitant systemic diseases?</p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient have a history of exposure to medications or chemicals?</p><p></p><p class="headingAnchor" id="H930319103"><span class="h3">History</span><span class="headingEndMark"> — </span>A detailed medical history should be obtained from the patient to determine if the hypopigmentation is related to an underlying disease. Patients should also be questioned about occupational and/or hobby-related exposure to chemicals that may cause hypopigmentation. The course of the disorder can help distinguish acquired hypopigmentations (which often show progression or regression) from inherited disorders (which are usually stable).</p><p class="headingAnchor" id="H2092733610"><span class="h3">Skin examination</span><span class="headingEndMark"> — </span>In all patients with hypopigmentation disorders, a complete skin examination should be performed under visible light and Wood's light  (<a class="graphic graphic_algorithm graphicRef108830" href="/d/graphic/108830.html" rel="external">algorithm 1</a>). Important clinical parameters include:</p><p class="bulletIndent1"><span class="glyph">●</span>Extent of the pigmentary abnormality (localized versus diffuse)</p><p class="bulletIndent1"><span class="glyph">●</span>Morphology of individual lesions</p><p class="bulletIndent1"><span class="glyph">●</span>Distribution (eg, sun-exposed areas, areas previously involved by inflammatory processes)</p><p class="bulletIndent1"><span class="glyph">●</span>Pattern (eg, linear, reticular, nonfigurate)</p><p></p><p class="headingAnchor" id="H3155787120"><span class="h3">Wood's light examination</span><span class="headingEndMark"> — </span>A Wood's lamp emits ultraviolet A light with a peak emission at 365 nm ("black light") that allows a better visualization of variations in skin pigmentation [<a href="#rid6">6</a>]. Patients should be examined in a darkened room with the light source held at 4 to 5 inches from the skin. (See  <a class="medical medical_review" href="/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Wood's lamp examination (black light)'</a>.) </p><p>Under Wood's light, depigmented lesions due to complete absence of melanin, such as vitiligo lesions, appear bright white and sharply delineated, as a result of the autofluorescence of dermal collagen. Hypopigmented lesions due to decreased melanin in the epidermis are also markedly enhanced. In contrast, hypopigmentations due to vascular causes (eg, nevus anemicus), in which the epidermal melanin content is normal, are not accentuated. </p><p>Examination under a Wood's lamp is especially helpful in fair-skinned individuals to identify hypopigmented or depigmented lesions that may not be visible to the naked eye  (<a class="graphic graphic_algorithm graphicRef108830" href="/d/graphic/108830.html" rel="external">algorithm 1</a>). </p><p class="headingAnchor" id="H3358519061"><span class="h3">Skin biopsy</span><span class="headingEndMark"> — </span>A skin biopsy for histopathologic evaluation is not routinely performed for the diagnosis of hypopigmentation disorders. However, a skin biopsy may be warranted if the clinical diagnosis is uncertain or there is a suspicion for hypopigmented mycosis fungoides. (See <a class="local">'Hypopigmented mycosis fungoides'</a> below.)</p><p>Standard stains (eg, hematoxylin and eosin, Fontana-Masson silver stain) and histochemical techniques (eg, Mart-1, Melan-A) can be used to evaluate the number and location of melanocytes and melanin granules in the epidermis and dermis.</p><p class="headingAnchor" id="H3074307261"><span class="h1">LOCALIZED DEPIGMENTATION</span></p><p class="headingAnchor" id="H719407036"><span class="h2">Chemical leukoderma</span><span class="headingEndMark"> — </span>Chemical leukoderma, also known as contact leukoderma, contact vitiligo, or chemical vitiligo, may result from occupational exposure to chemicals that have a specific melanocytotoxic effect [<a href="#rid7">7,8</a>]. The majority of these chemicals are derivatives of phenols and catechols such as para-tertiary butylphenol, para-tertiary butyl catechol, monobenzyl ether of <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> (MBEH; monobenzone), and hydroquinone [<a href="#rid9">9,10</a>]. They may be found in rubber gloves and other rubber products, germicides, insecticides, adhesives, hair dyes, and clothing treated with azo dyes.</p><p>Many other substances have also been reported to cause chemical leukoderma, including sulfhydryls, mercurials (eg, thimerosal, used as a preservative in cosmetics or topical medications), and cinnamic aldehyde (a fragrance used in personal care products). Household exposure to these chemicals may be more common than occupational exposure in some countries [<a href="#rid10">10</a>] However, not all exposed individuals develop leukoderma, suggesting a variability in the individual susceptibility [<a href="#rid11">11</a>].</p><p>The depigmentation starts on the hands and forearms (which are the presumptive sites of contact) as small, confetti-like white macules that tend to spread and coalesce  (<a class="graphic graphic_picture graphicRef107622" href="/d/graphic/107622.html" rel="external">picture 1</a>). However, depigmentation can also occur in areas distant from the sites of exposure (chemical leukoderma syndrome). (See <a class="local">'Diffuse depigmentation'</a> below.)</p><p>Histopathologically, chemical leukoderma is indistinguishable from vitiligo. In patients presenting with multiple pea-like or confetti-like depigmented macules, a history of repeated exposure to melanocytotoxic chemicals is an important clue to the diagnosis.</p><p>Strict avoidance of the offending substance may lead to spontaneous repigmentation in some patients. Topical corticosteroids and narrowband ultraviolet B phototherapy have been reported as effective in some but not all patients. Depigmentation may be permanent.</p><p class="headingAnchor" id="H4223074570"><span class="h2">Drug-induced leukoderma</span><span class="headingEndMark"> — </span>Potent topical or intralesional corticosteroids may induce hypopigmentation at the site of application, particularly in darkly pigmented individuals [<a href="#rid12">12,13</a>]. Depigmentation mimicking vitiligo has been reported in patients treated with the epidermal growth factor receptor inhibitor <a class="drug drug_general" data-topicid="8712" href="/d/drug information/8712.html" rel="external">gefitinib</a> [<a href="#rid14">14</a>], the tyrosine kinase inhibitor <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> mesylate [<a href="#rid15">15,16</a>], immune checkpoint inhibitors [<a href="#rid17">17,18</a>], pegylated interferon [<a href="#rid19">19</a>], topical <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> [<a href="#rid20">20,21</a>], and transdermal <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a> [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors", section on 'Vitiligo-like depigmentation'</a>.)</p><p class="headingAnchor" id="H1526142568"><span class="h2">Halo nevus</span><span class="headingEndMark"> — </span>Halo nevus, also called "leukoderma acquisitum centrifugum," refers to the development of a halo of depigmentation around a melanocytic nevus  (<a class="graphic graphic_picture graphicRef57744 graphicRef65988" href="/d/graphic/57744.html" rel="external">picture 2A-B</a>) [<a href="#rid23">23</a>]. This pigment loss often heralds the spontaneous regression of the central nevus, which is thought to be a T cell-mediated immune response to nevus antigens [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/4846.html" rel="external">"Acquired melanocytic nevi (moles)"</a> and  <a class="medical medical_review" href="/d/html/4846.html" rel="external">"Acquired melanocytic nevi (moles)", section on 'Halo nevi'</a>.)</p><p class="headingAnchor" id="H3679066352"><span class="h2">Melanoma-associated leukoderma</span><span class="headingEndMark"> — </span>Melanoma-associated leukoderma has been reported in approximately 3 percent of patients with melanoma [<a href="#rid25">25</a>]. It can occur spontaneously in the absence of treatment or follow treatment with various immunotherapies. Leukoderma has been reported in patients with advanced disease treated with high-dose interleukin (IL) 2 [<a href="#rid26">26</a>], interferon-alpha [<a href="#rid27">27</a>], anti-programmed cell death protein 1 (anti-PD-1; eg, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>) and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4; <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>) immune checkpoint inhibitors, and IL-2 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) [<a href="#rid17">17,18,25,28,29</a>]. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.) </p><p>However, in some patients, the hypopigmentation may precede the diagnosis of melanoma by years, while in others, it may appear concurrently with the diagnosis of metastatic disease.</p><p>Melanoma-associated leukoderma can occur around the primary tumor or cutaneous metastases or at distant sites, mimicking vitiligo. However, in contrast with vitiligo, lesions can be either hypopigmented or depigmented and tend to be extensive, patchy, and asymmetric  (<a class="graphic graphic_picture graphicRef132633" href="/d/graphic/132633.html" rel="external">picture 3</a>). Whether the occurrence of leukoderma in patients with melanoma is associated with a more favorable prognosis or response to therapy against melanoma remains uncertain [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors", section on 'Vitiligo-like depigmentation'</a>.)</p><p>The pathogenesis of melanoma-associated leukoderma is incompletely understood. Evidence suggests that it represents the host immune response against the tumor. Melanoma is a highly immunogenic tumor that commonly overexpresses several melanocytic lineage antigens such as tyrosinase, tyrosinase-related protein (TRP)-1, TRP-2, gp100, and melanoma antigen recognized by T cells [<a href="#rid31">31</a>]. A cytotoxic T cell response against these "self" antigens can cause destruction of normal melanocytes expressing normal levels of these proteins.</p><p class="headingAnchor" id="H714393310"><span class="h1">DIFFUSE DEPIGMENTATION</span><span class="headingEndMark"> — </span>Diffuse depigmented lesions are usually seen in patients with generalized vitiligo. However, in some patients with chemical leukoderma, the depigmentation can spread from the site of contact with the offending chemical or even develop at distant sites, sometimes when patients are no longer exposed to the offending chemical [<a href="#rid7">7,32,33</a>]. It is difficult or impossible to determine whether these patients have a true diffuse chemical leukoderma or generalized vitiligo that was triggered by the contact with a toxic chemical [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/105109.html" rel="external">"Vitiligo: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3378949613"><span class="h1">LOCALIZED HYPOPIGMENTATION</span></p><p class="headingAnchor" id="H201683538"><span class="h2">Postinflammatory hypopigmentation</span></p><p class="headingAnchor" id="H278459835"><span class="h3">General features</span><span class="headingEndMark"> — </span>Postinflammatory hypopigmentation is an acquired partial or total loss of skin pigmentation that may occur following the resolution of a wide range of inflammatory or infectious dermatoses  (<a class="graphic graphic_algorithm graphicRef108830" href="/d/graphic/108830.html" rel="external">algorithm 1</a>) [<a href="#rid34">34</a>]. Contact with irritants and dermatologic or cosmetic procedures such as cryosurgery, laser therapy, or laser resurfacing may also induce postinflammatory hypopigmentation or depigmentation.</p><p>The pathogenesis of postinflammatory hypopigmentation is incompletely understood. Cutaneous inflammation can affect all steps of melanogenesis, particularly the transfer of melanosomes to keratinocytes [<a href="#rid35">35</a>]. Severe inflammation may lead to a loss of functional melanocytes or melanocyte death [<a href="#rid34">34</a>].</p><p>Postinflammatory hypopigmentation typically presents with hypomelanotic macules or patches that match the shape and distribution of previous inflammatory lesions  (<a class="graphic graphic_picture graphicRef101382" href="/d/graphic/101382.html" rel="external">picture 4</a>). In most cases, inflammatory lesions may be seen along with hypopigmented lesions. Complete pigment loss can be seen in scleroderma or lupus erythematosus lesions. </p><p>The diagnosis is in most cases clinical. Examination under Wood's light accentuates lesions. However, a skin biopsy of an inflammatory lesion, if present, may be helpful in identifying the underlying condition if the diagnosis is unclear or if there is a clinical suspicion of mycosis fungoides. Histologic findings can differ depending on the characteristics of the preceding, inflammatory condition. Epidermal melanin and/or number of epidermal melanocytes is decreased, although melanin primarily located in macrophages (melanophages) can be observed in the upper dermis and around the vessels in the upper dermis. </p><p>Postinflammatory hypopigmentation is usually reversible and resolves spontaneously over weeks to months after the resolution of the underlying condition. Depigmented lesions resulting from complete loss of melanocytes do not improve with time. In these cases, epidermal grafting may be a therapeutic option.</p><p class="headingAnchor" id="H2110840350"><span class="h3">Pityriasis alba</span><span class="headingEndMark"> — </span>Pityriasis alba is a common, benign dermatosis that occurs predominantly in children and adolescents and is more noticeable in those with darker skin types [<a href="#rid36">36,37</a>]. Although considered in many cases a minor manifestation of atopic dermatitis, pityriasis alba may also occur in nonatopic individuals [<a href="#rid38">38</a>]. </p><p>Pityriasis alba typically presents with multiple asymptomatic hypopigmented macules and patches, round or oval in shape, involving predominantly the face, upper trunk, and upper limbs  (<a class="graphic graphic_picture graphicRef60866 graphicRef134841" href="/d/graphic/60866.html" rel="external">picture 5A-B</a>). Mild erythema and scaling may precede the development of hypopigmentation.</p><p>On histopathologic examination, changes are mild and nonspecific and consist of mild spongiosis, acanthosis, and hyperkeratosis. There is markedly reduced pigment in the epidermis without significant reduction in melanocyte count [<a href="#rid36">36</a>]. On electron microscopy, degenerative changes in melanocytes and a reduced number of melanosomes within keratinocytes have been seen [<a href="#rid36">36</a>]. </p><p>The diagnosis is in most cases straightforward, based upon the clinical appearance and distribution of lesions in patients. On examination with a Wood's lamp, lesions are accentuated but nonfluorescent. The differential diagnosis includes postinflammatory hypopigmentation following psoriasis or atopic eczema, tinea versicolor, nevus depigmentosus, nevus anemicus, hypopigmented mycosis fungoides, and vitiligo. </p><p>Pityriasis alba is a self-limited disease, but the time to resolution varies from several months to a few years. Treatment with emollients and low-potency topical corticosteroids may be beneficial in some patients. Topical calcineurin inhibitors may be an alternative to topical corticosteroids for the treatment of facial lesions [<a href="#rid39">39</a>]. </p><p>There is a single report on the use of targeted phototherapy for pityriasis alba [<a href="#rid40">40</a>]. In this small observational study, targeted phototherapy with a 308 nm excimer laser induced complete remission in 10 of 12 children with moderate to severe facial pityriasis alba.</p><p class="headingAnchor" id="H2337713554"><span class="h3">Lichen striatus albus</span><span class="headingEndMark"> — </span>Lichen striatus albus is a variant of lichen striatus presenting with hypopigmented macules and patches arranged in a linear pattern along the lines of Blaschko  (<a class="graphic graphic_picture graphicRef94731" href="/d/graphic/94731.html" rel="external">picture 6</a>). The clinical features, diagnosis, and treatment of lichen striatus are discussed separately. (See  <a class="medical medical_review" href="/d/html/13731.html" rel="external">"Lichen striatus"</a>.) </p><p class="headingAnchor" id="H738757529"><span class="h3">Scleroderma</span><span class="headingEndMark"> — </span>Skin hyperpigmentation or depigmentation ("salt and pepper") is seen in patients with scleroderma, usually in combination with other cutaneous manifestations of the disease  (<a class="graphic graphic_picture graphicRef107762" href="/d/graphic/107762.html" rel="external">picture 7</a>). (See  <a class="medical medical_review" href="/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p class="headingAnchor" id="H2743903190"><span class="h3">Extragenital lichen sclerosus</span><span class="headingEndMark"> — </span>Extragenital lichen sclerosus is a chronic inflammatory disorder affecting predominantly women in the fifth or sixth decade of life. It is characterized by the presence of asymptomatic, porcelain-white, atrophic plaques most commonly located on the back  (<a class="graphic graphic_picture graphicRef74154" href="/d/graphic/74154.html" rel="external">picture 8</a>), chest  (<a class="graphic graphic_picture graphicRef60332" href="/d/graphic/60332.html" rel="external">picture 9</a>), shoulder, neck, wrists  (<a class="graphic graphic_picture graphicRef107703" href="/d/graphic/107703.html" rel="external">picture 10</a> and <a class="graphic graphic_picture graphicRef70580" href="/d/graphic/70580.html" rel="external">picture 11</a>), thigh, and inframammary areas. Early lesions appear as flat-topped and slightly scaly, hypopigmented, white, or mildly erythematous polygonal papules that may coalesce to form larger plaques  (<a class="graphic graphic_picture graphicRef58815" href="/d/graphic/58815.html" rel="external">picture 12</a>). </p><p>The diagnosis, differential diagnosis, and treatment of extragenital lichen sclerosus is discussed separately. (See  <a class="medical medical_review" href="/d/html/15838.html" rel="external">"Extragenital lichen sclerosus: Clinical features and diagnosis"</a>.) </p><p class="headingAnchor" id="H2369631112"><span class="h3">Discoid lupus erythematosus</span><span class="headingEndMark"> — </span>The inflammatory lesions of discoid lupus erythematosus heal leaving depressed, atrophic scars, telangiectasias, and hyperpigmentation and/or hypopigmentation  (<a class="graphic graphic_picture graphicRef107705" href="/d/graphic/107705.html" rel="external">picture 13</a>). Histologically, the depigmented lesions show degeneration of basal layer with epidermal atrophy, a variable number of melanocytes, and pigmentary incontinence in the superficial dermis. (See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus"</a>.)</p><p class="headingAnchor" id="H2315141384"><span class="h3">Sarcoidosis</span><span class="headingEndMark"> — </span>Hypopigmented sarcoidosis is a rare subtype of cutaneous sarcoidosis seen predominantly in dark-skinned individuals. It presents with thin, nonscaly papules or plaques, 1 to 10 mm in diameter, most often located on the trunk and face  (<a class="graphic graphic_picture graphicRef74163 graphicRef63313" href="/d/graphic/74163.html" rel="external">picture 14A-B</a>) [<a href="#rid41">41</a>]. Erythematous or skin-colored papules are sometimes present in the center of the patch, giving the lesion a "fried egg" appearance. Histopathologic examination of a skin biopsy reveals characteristic noncaseating sarcoidal granulomas, consisting of aggregates of epithelioid histiocytes, giant cells, and mature macrophages  (<a class="graphic graphic_picture graphicRef80383" href="/d/graphic/80383.html" rel="external">picture 15</a> and <a class="graphic graphic_picture graphicRef54204" href="/d/graphic/54204.html" rel="external">picture 16</a>). </p><p>The clinical manifestations, diagnosis, and differential diagnosis of cutaneous sarcoidosis are presented in detail separately. (See  <a class="medical medical_review" href="/d/html/13762.html" rel="external">"Cutaneous manifestations of sarcoidosis"</a>.)</p><p class="headingAnchor" id="H1642460080"><span class="h3">Hypopigmented mycosis fungoides</span><span class="headingEndMark"> — </span>Hypopigmented mycosis fungoides (HMF) is an uncommon variant of mycosis fungoides, mostly seen in children and in patients with darker skin types [<a href="#rid42">42,43</a>]. HMF presents with hypopigmented, scaly patches mainly distributed on the trunk, pelvic girdle, buttocks, and proximal portions of the extremities. In some patients, scaling may be minimal or absent, and lesions may mimic vitiligo [<a href="#rid44">44,45</a>]. HMF may also simulate pityriasis alba, pityriasis lichenoides, tinea versicolor, or leprosy.</p><p>The diagnosis of HMF is difficult and often delayed. Repeated skin biopsies for histopathologic, immunophenotypic, and molecular studies are often required for a correct diagnosis. (See  <a class="medical medical_review" href="/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p class="headingAnchor" id="H2123107444"><span class="h3">Pityriasis lichenoides chronica</span><span class="headingEndMark"> — </span>Pityriasis lichenoides chronica is an inflammatory skin disease characterized by the development of multiple scaly, erythematous to brown papules on the trunk and extremities. Occasionally, patients present with widespread hypopigmented macules as the predominant clinical manifestation of the disease  (<a class="graphic graphic_picture graphicRef89408" href="/d/graphic/89408.html" rel="external">picture 17</a>) [<a href="#rid46">46</a>]. A skin biopsy can confirm the diagnosis. (See  <a class="medical medical_review" href="/d/html/15287.html" rel="external">"Pityriasis lichenoides chronica"</a>.)</p><p class="headingAnchor" id="H4227767181"><span class="h2">Infectious hypomelanoses</span></p><p class="headingAnchor" id="H1387144714"><span class="h3">Tinea versicolor</span><span class="headingEndMark"> — </span>Tinea versicolor (pityriasis versicolor) is a common, recurrent, superficial fungal disease most commonly occurring in adolescents and young adults that is caused by <em>Malassezia</em> yeasts, a component of normal skin flora [<a href="#rid47">47,48</a>]. Tinea versicolor can present with hypopigmented  (<a class="graphic graphic_picture graphicRef100021" href="/d/graphic/100021.html" rel="external">picture 18</a>), hyperpigmented  (<a class="graphic graphic_picture graphicRef100022" href="/d/graphic/100022.html" rel="external">picture 19</a>), or erythematous macules  (<a class="graphic graphic_picture graphicRef100020" href="/d/graphic/100020.html" rel="external">picture 20</a>) and patches involving predominantly the upper trunk. Inhibitory or damaging effects on melanocytes by <a class="drug drug_general" data-topicid="9038" href="/d/drug information/9038.html" rel="external">azelaic acid</a> (a dicarboxylic acid produced by <em>Malassezia</em>) may play a role in the development of hypopigmentation. </p><p>The diagnosis is in most cases clinical but may be confirmed with a potassium hydroxide preparation showing hyphae and yeast cells in a pattern described as "spaghetti and meatballs"  (<a class="graphic graphic_picture graphicRef58965" href="/d/graphic/58965.html" rel="external">picture 21</a>). Examination with a Wood's lamp will reveal a yellow to yellow-green fluorescence in approximately one-third of cases [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/4039.html" rel="external">"Tinea versicolor (pityriasis versicolor)"</a>.)</p><p class="headingAnchor" id="H817696961"><span class="h3">Leprosy</span><span class="headingEndMark"> — </span>Indeterminate (early) leprosy presents in most cases with ill-defined hypopigmented macules or patches with diminished sensation  (<a class="graphic graphic_picture graphicRef60828 graphicRef107756 graphicRef107757" href="/d/graphic/60828.html" rel="external">picture 22A-C</a>) [<a href="#rid50">50,51</a>]. Hair loss, mild atrophy, and reduced or absent sweating may also be present in the affected area. </p><p>The lack of sensory perception to a light touch or pinprick distinguishes leprosy lesions from vitiligo and other infectious and noninfectious hypomelanoses. (See  <a class="medical medical_review" href="/d/html/5348.html" rel="external">"Leprosy: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3321602934"><span class="h3">Endemic treponematoses</span><span class="headingEndMark"> — </span>Endemic treponematoses, which include yaws, bejel, and pinta, are chronic bacterial infections caused by organisms that are morphologically and serologically indistinguishable from <em>Treponema pallidum</em>, the causative agent of syphilis [<a href="#rid52">52,53</a>]. (See  <a class="medical medical_review" href="/d/html/87120.html" rel="external">"Yaws, bejel, and pinta"</a>.)</p><p>Pinta is confined to the skin and is the mildest of the treponematoses, affecting both children and adults. Secondary lesions of pinta may remain active for several years and lead to extensive depigmentation resembling vitiligo  (<a class="graphic graphic_picture graphicRef89991 graphicRef88926" href="/d/graphic/89991.html" rel="external">picture 23A-B</a>). Yaws affects predominantly children. Secondary lesions of yaws consist of papules, plaques, or papillomatous lesions that may ulcerate and leave oval hypopigmented macules  (<a class="graphic graphic_picture graphicRef88927" href="/d/graphic/88927.html" rel="external">picture 24</a>).</p><p class="headingAnchor" id="H3995969917"><span class="h3">Syphilis</span><span class="headingEndMark"> — </span>Leukoderma syphiliticum may rarely occur following the resolution of classic papular lesions of secondary syphilis [<a href="#rid54">54</a>]. The diagnosis is suspected in patients with a history of primary syphilis or in patients with additional cutaneous lesions characteristic of secondary syphilis. On histopathologic examination, the presence of a band-like lymphoplasmacytic infiltrate in the upper dermis may represent a clue to the diagnosis. Serologic testing for syphilis will confirm the diagnosis. </p><p class="headingAnchor" id="H1366952336"><span class="h3">Onchocerciasis</span><span class="headingEndMark"> — </span>Onchocerciasis, also known as "river blindness," is caused by the filarial nematode <em>Onchocerca volvulus</em>. It affects rural communities and is a major cause of blindness and skin disease in endemic areas. Manifestations of onchocercal skin disease include generalized itching, acute or chronic papular onchodermatitis, lichenified onchodermatitis, skin atrophy, and depigmentation. </p><p>Depigmentation typically occurs on the anterior shins of older adults. Patches of complete pigment loss present perifollicular "spots" or islands of normally pigmented skin, resulting in the so-called "leopard skin" appearance  (<a class="graphic graphic_picture graphicRef107761" href="/d/graphic/107761.html" rel="external">picture 25</a>). (See  <a class="medical medical_review" href="/d/html/5683.html" rel="external">"Onchocerciasis"</a>.)</p><p class="headingAnchor" id="H2631197494"><span class="h2">Nevus depigmentosus</span><span class="headingEndMark"> — </span>Nevus depigmentosus  (<a class="graphic graphic_picture graphicRef108149 graphicRef106603 graphicRef59799" href="/d/graphic/108149.html" rel="external">picture 26A-C</a>) is a circumscribed, segmental area of depigmentation or hypopigmentation usually present at birth or detected in the first years of life [<a href="#rid55">55,56</a>]. The lesion is usually solitary and shows little change over time, although it may enlarge as the patient grows. The well-defined, hypopigmented macule has an irregular, saw-toothed border, but hairs within the lesion generally remain pigmented.</p><p>Nevus depigmentosus is a form of cutaneous mosaicism, caused by an altered clone of melanocytes with a decreased ability to produce melanin, abnormal melanosomes, and inability to transfer pigment to keratinocytes. When examined under a Wood's lamp, nevus depigmentosus shows an off-white accentuation, in contrast with the bright-white fluorescence seen in vitiligo. Nevus depigmentosus may be confused with the ash-leaf spots of tuberous sclerosis complex (TSC)  (<a class="graphic graphic_picture graphicRef91042" href="/d/graphic/91042.html" rel="external">picture 27</a>). However, the ash-leaf spots are usually multiple and associated with other cutaneous and extracutaneous features of TSC. (See  <a class="medical medical_review" href="/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>.)</p><p class="headingAnchor" id="H2846196395"><span class="h2">Localized hypopigmentations due to vascular causes</span></p><p class="headingAnchor" id="H3833012404"><span class="h3">Nevus anemicus</span><span class="headingEndMark"> — </span>Nevus anemicus is a congenital, localized, cutaneous vascular anomaly presenting as a pale, irregularly shaped patch on otherwise normal skin  (<a class="graphic graphic_picture graphicRef108038" href="/d/graphic/108038.html" rel="external">picture 28</a>). It is thought to be caused by a localized increased vascular sensitivity to endogenous catecholamines resulting in persistent vasoconstriction [<a href="#rid57">57,58</a>]. Nevus anemicus is in most cases an isolated finding but may occur in association with several genetic syndromes, including phakomatosis pigmentovascularis, neurofibromatosis, and TSC [<a href="#rid59">59-61</a>]. </p><p>Nevus anemicus is not accentuated by Wood's light. On diascopy, which consists in applying pressure to the lesion and adjacent normal skin with a glass slide, nevus anemicus is indistinguishable from the blanched adjacent skin.</p><p>There are no treatments for nevus anemicus. Camouflage makeup may be an effective treatment for those patients who feel uncomfortable with its appearance.</p><p class="headingAnchor" id="H2756690912"><span class="h3">Bier spots</span><span class="headingEndMark"> — </span>Bier spots, also called physiologic anemic macules, represent an uncommon, benign vascular mottling of the skin [<a href="#rid62">62</a>]. They are thought to be an exaggerated physiologic vasoconstrictive response of the small cutaneous vessels to hypoxia induced by venous stasis or venous hypertension [<a href="#rid63">63,64</a>].</p><p>Bier spots present with multiple asymptomatic, small, and irregular white macules on a background of blanching erythema, predominantly located on the arms and legs of young adults  (<a class="graphic graphic_picture graphicRef108043" href="/d/graphic/108043.html" rel="external">picture 29</a>) [<a href="#rid65">65</a>]. Bier spots are usually an isolated finding in patients otherwise healthy. There are a few reports of association with deep vein thrombosis [<a href="#rid66">66</a>], lower extremity lymphedema [<a href="#rid67">67</a>], cyanosis and urticarial eruption [<a href="#rid68">68</a>], and cryoglobulinemia [<a href="#rid69">69</a>].</p><p>The diagnosis is clinical, based upon the disappearance of the white lesions on diascopy or with limb elevation. The observation that lesions are accentuated by placing a tourniquet around the affected limb and disappear after the tourniquet is removed is an additional clue to the diagnosis. </p><p>No treatment is required for Bier spots. Patients should be reassured about the benign and self-limited nature of the condition.</p><p class="headingAnchor" id="H26765536"><span class="h1">DIFFUSE HYPOPIGMENTATION</span></p><p class="headingAnchor" id="H1001236044"><span class="h2">Vitiligo-like depigmentation associated with PD-1 inhibitors</span><span class="headingEndMark"> — </span>Vitiligo-like lesions have been reported in patients receiving programmed cell death protein 1 (PD-1) inhibitors [<a href="#rid70">70</a>]. It is thought that these lesions share similar clinical features and mechanisms as vitiligo. (See  <a class="medical medical_review" href="/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors"</a>.)</p><p class="headingAnchor" id="H3285989778"><span class="h2">Idiopathic guttate hypomelanosis</span><span class="headingEndMark"> — </span>Idiopathic guttate hypomelanosis (IGH) is a common hypopigmentation disorder characterized by small, round or oval, white macules that typically presents in middle-aged and older individuals  (<a class="graphic graphic_picture graphicRef108026" href="/d/graphic/108026.html" rel="external">picture 30C</a>). Its prevalence increases with age and is estimated to be around 70 to more than 80 percent in individuals older than 40 [<a href="#rid71">71,72</a>]. IGH affects predominantly individuals with light skin types, without sex predilection.</p><p>Patients present with multiple small, scattered, discrete, round- or oval-shaped macules 2 to 6 mm in size that are lighter than the surrounding skin  (<a class="graphic graphic_picture graphicRef67346 graphicRef61761" href="/d/graphic/67346.html" rel="external">picture 30A-B</a>). The surface of the lesions is usually smooth but may be occasionally scaly. IGH most commonly appears on sun-exposed areas, such as the anterior area of the lower extremities and outer surface of forearms. However, sun-protected areas and, rarely, the face can also be affected.</p><p>The exact cause of IGH is unknown. One hypothesis is that it results from chronic ultraviolet exposure in combination with the normal aging process [<a href="#rid73">73,74</a>]. However, trauma is still regarded as a triggering factor.</p><p>Histopathologically, IGH lesions demonstrate reduced number of melanocytes, decreased melanin pigment, and hyperkeratosis with flattened rete ridge [<a href="#rid75">75-77</a>]. An electron microscopy study suggests that IGH may be due to a functional defect in the transfer of melanosomes to keratinocytes, in the absence of structural melanocyte abnormalities [<a href="#rid78">78</a>].</p><p>IGH lesions usually do not increase in size, but their number increases with age. Spontaneous repigmentation has not been observed. Although treatment is not typically required, a variety of therapies have been tried for cosmetic reasons with inconsistent results, including topical calcineurin inhibitors [<a href="#rid79">79-81</a>], fractional carbon dioxide laser [<a href="#rid81">81-84</a>], phenol [<a href="#rid85">85</a>], <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> tattooing [<a href="#rid86">86</a>], and cryotherapy [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H3628327051"><span class="h2">Progressive macular hypomelanosis</span><span class="headingEndMark"> — </span>Progressive macular hypomelanosis (PMH) is a relatively common skin disorder characterized by ill-defined, nonscaly hypopigmented macules typically located on the trunk around the midline  (<a class="graphic graphic_picture graphicRef108028 graphicRef108030" href="/d/graphic/108028.html" rel="external">picture 31A-B</a>)<strong> </strong>[<a href="#rid88">88</a>]. Rarely, PMH may involve the upper extremities and the head and neck area. PMH typically occurs in adolescents and young adults and is most frequent in females and in individuals with darker skin types.</p><p>The precise etiology and pathogenesis of PMH are unknown. <em>Cutibacterium</em> (formerly <em>Propionibacterium</em>) <em>acnes</em> or different<em> </em>subtypes of <em>Cutibacterium</em> species (anaerobic saprophytes of the human skin residing within the hair follicles) have been proposed as etiologic agents [<a href="#rid88">88-91</a>]. The electron microscopy finding of smaller and less melanized melanosomes in lesional skin, compared with normal skin, suggests a decreased melanin synthesis as the cause of hypopigmentation [<a href="#rid92">92,93</a>]. However, the role of <em>C. acnes</em> in the altered melanogenesis remains to be determined.</p><p>The diagnosis of PMH is usually clinical. Under Wood's light, the hypopigmented lesions often demonstrate a characteristic, punctiform, orange-red, follicular fluorescence. The examination of a potassium hydroxide preparation is typically negative. If performed, histologic examination of a skin biopsy shows decreased epidermal melanin content with a normal number of melanocytes [<a href="#rid94">94</a>].</p><p>Treatment for PMH is difficult. Therapies that have been used with inconsistent results include topical antibacterials (eg, 5% <a class="drug drug_general" data-topicid="8811" href="/d/drug information/8811.html" rel="external">benzoyl peroxide</a> gel, 1% <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> lotion) and phototherapy with ultraviolet A (UVA) or narrowband ultraviolet B [<a href="#rid95">95</a>], alone or in combination [<a href="#rid95">95-98</a>]. PMH may resolve spontaneously after the age of 40.</p><p class="headingAnchor" id="H1772198017"><span class="h2">Leukoderma punctata</span><span class="headingEndMark"> — </span>Some patients develop multiple punctiform, hypopigmented or achromic spots 0.5 to 1.5 mm in diameter after long-term topical or systemic psoralen plus UVA treatment [<a href="#rid99">99-102</a>]. Histologic examination shows a reduction in melanin content and melanocyte number. Leukoderma punctata is thought to be caused by phototoxic damage of keratinocytes and melanocytes.</p><p class="headingAnchor" id="H93826055"><span class="h2">Nutritional deficiencies</span><span class="headingEndMark"> — </span>In children, severe protein malnutrition (kwashiorkor) may be associated with hypopigmentation of the skin and scalp hair [<a href="#rid103">103</a>]. Alternating bands of light and dark hair may result from alternating periods of malnutrition and adequate nutritional intake. (See  <a class="medical medical_review" href="/d/html/5883.html" rel="external">"Malnutrition in children in resource-limited settings: Clinical assessment", section on 'Kwashiorkor (edematous malnutrition)'</a>.)</p><p>Although the precise mechanism leading to decreased melanin production is not known, a reduced availability of tyrosine is thought to be a contributory factor. Vitamin B12, iron, and copper deficiency may also be associated with diffuse hypopigmentation with involvement of the scalp hair [<a href="#rid104">104</a>]. </p><p class="headingAnchor" id="H504092255"><span class="h2">Endocrine disorders</span><span class="headingEndMark"> — </span>The association of vitiligo with autoimmune endocrine disorders is well recognized. However, hypopigmentations other than vitiligo and pallor have been reported in patients with hypopituitarism, hypogonadism, and Cushing syndrome [<a href="#rid104">104</a>]. In patients with hypopituitarism, the light pigmentation is thought to result from a decreased production of melanocyte-stimulating hormone (MSH) and adrenocorticotrophic hormone (ACTH). In patients with ACTH-independent Cushing syndrome, depigmentation may result from suppressed pituitary production of MSH by high cortisol levels [<a href="#rid105">105</a>]. (See  <a class="medical medical_review" href="/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H2463457479"><span class="h2">Other</span><span class="headingEndMark"> — </span>A diffusely pale skin is a normal finding in patients with fair skin complexions. However, a diffuse skin pallor, especially if associated with pallor of the nail beds or conjunctivae, may be a sign of anemia. (See  <a class="medical medical_review" href="/d/html/6447.html" rel="external">"Evaluation of pallor in children"</a> and  <a class="medical medical_review" href="/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>.)</p><p class="headingAnchor" id="H1858459271"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – "Hypopigmentation" is a general term that refers to any form of decreased or absent skin pigmentation, while "hypomelanosis" more specifically refers to a reduction of epidermal melanin. Hypopigmentation disorders may be congenital or acquired, diffuse or localized, and may occur in isolation or be associated with a wide range of congenital or acquired disorders. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – In many cases, the diagnosis of hypopigmentation disorders is made on clinical grounds, based upon a detailed history and physical examination. The lesion morphology, color (depigmented or hypopigmented), distribution, and pattern are important clues to the diagnosis  (<a class="graphic graphic_algorithm graphicRef108830" href="/d/graphic/108830.html" rel="external">algorithm 1</a>). However, examination under Wood's light, a skin biopsy, and additional laboratory tests may be required if the clinical diagnosis is uncertain. (See <a class="local">'Diagnostic approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localized depigmentation</strong> – Localized depigmentations other than vitiligo are uncommon and include chemical leukoderma  (<a class="graphic graphic_picture graphicRef107622" href="/d/graphic/107622.html" rel="external">picture 1</a>), drug-induced leukoderma, and melanoma-associated leukoderma. (See <a class="local">'Localized depigmentation'</a> above and <a class="local">'Diffuse depigmentation'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localized hypopigmentation</strong> – Localized hypopigmentation may occur following inflammatory dermatoses  (<a class="graphic graphic_picture graphicRef101382" href="/d/graphic/101382.html" rel="external">picture 4</a>) or dermatologic procedures (eg, cryotherapy, laser therapy). Skin infections, including tinea versicolor  (<a class="graphic graphic_picture graphicRef100021" href="/d/graphic/100021.html" rel="external">picture 18</a>), leprosy  (<a class="graphic graphic_picture graphicRef107756" href="/d/graphic/107756.html" rel="external">picture 22B</a>), and onchocerciasis  (<a class="graphic graphic_picture graphicRef107761" href="/d/graphic/107761.html" rel="external">picture 25</a>), are also frequent causes of localized hypopigmentation. (See <a class="local">'Postinflammatory hypopigmentation'</a> above and <a class="local">'Infectious hypomelanoses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse hypopigmentation</strong> – Relatively common causes of diffuse macular hypopigmentation include idiopathic guttate hypomelanosis  (<a class="graphic graphic_picture graphicRef67346 graphicRef61761 graphicRef108026" href="/d/graphic/67346.html" rel="external">picture 30A-C</a>) and progressive macular hypomelanosis  (<a class="graphic graphic_picture graphicRef108028" href="/d/graphic/108028.html" rel="external">picture 31A</a>). Vitiligo-like lesions have been reported in patients receiving immune checkpoint inhibitors. (See  <a class="medical medical_review" href="/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors"</a>.)</p><p></p><p class="bulletIndent1">Diffuse hypopigmentation often also involving the scalp hair may be seen in patients with severe protein malnutrition or iron, copper, or vitamin B12 deficiency and in patients with hypopituitarism, hypogonadism, or Cushing syndrome. (See <a class="local">'Diffuse hypopigmentation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Lapeere H, Boone B, De Schepper S, et al. Hypomelanoses and hypermelanoses. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith L, Katz SI, Gilchrest BA, et al (Eds), McGraw-Hill Medical, 2012. p.804.</li><li><a class="nounderline abstract_t">Tey HL. Approach to hypopigmentation disorders in adults. Clin Exp Dermatol 2010; 35:829.</a></li><li><a class="nounderline abstract_t">Tey HL. A practical classification of childhood hypopigmentation disorders. Acta Derm Venereol 2010; 90:6.</a></li><li><a class="nounderline abstract_t">Saleem MD, Oussedik E, Schoch JJ, et al. Acquired disorders with depigmentation: A systematic approach to vitiliginoid conditions. J Am Acad Dermatol 2019; 80:1215.</a></li><li><a class="nounderline abstract_t">Saleem MD, Oussedik E, Picardo M, Schoch JJ. Acquired disorders with hypopigmentation: A clinical approach to diagnosis and treatment. J Am Acad Dermatol 2019; 80:1233.</a></li><li><a class="nounderline abstract_t">Gupta LK, Singhi MK. Wood's lamp. Indian J Dermatol Venereol Leprol 2004; 70:131.</a></li><li><a class="nounderline abstract_t">Ghosh S, Mukhopadhyay S. Chemical leucoderma: a clinico-aetiological study of 864 cases in the perspective of a developing country. Br J Dermatol 2009; 160:40.</a></li><li><a class="nounderline abstract_t">Ghosh S. Chemical leukoderma: what's new on etiopathological and clinical aspects? Indian J Dermatol 2010; 55:255.</a></li><li><a class="nounderline abstract_t">Lerner EA, Sober AJ. Chemical and pharmacologic agents that cause hyperpigmentation or hypopigmentation of the skin. Dermatol Clin 1988; 6:327.</a></li><li><a class="nounderline abstract_t">Bonamonte D, Foti C, Romita P, et al. Colors and contact dermatitis. Dermatitis 2014; 25:155.</a></li><li><a class="nounderline abstract_t">English JS, Dawe RS, Ferguson J. Environmental effects and skin disease. Br Med Bull 2003; 68:129.</a></li><li><a class="nounderline abstract_t">Schwartz C, Javvaji S, Feinberg JS. Linear rays of hypopigmentation following intra-articular corticosteroid injection for post-traumatic degenerative joint disease. Dermatol Online J 2012; 18:11.</a></li><li><a class="nounderline abstract_t">Shah CP, Rhee D, Garg SJ. Eyelid cutaneous hypopigmentation after sub-tenon triamcinolone injection after retinal detachment repair. Retin Cases Brief Rep 2012; 6:271.</a></li><li><a class="nounderline abstract_t">Jalalat SZ, Cohen PR. Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation. Dermatol Online J 2013; 19:20020.</a></li><li><a class="nounderline abstract_t">Llamas-Velasco M, Fraga J, Kutzner H, et al. Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study. J Cutan Pathol 2014; 41:417.</a></li><li><a class="nounderline abstract_t">Aleem A. Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther 2009; 2:358.</a></li><li><a class="nounderline abstract_t">Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 2020; 83:1255.</a></li><li><a class="nounderline abstract_t">Larsabal M, Marti A, Jacquemin C, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol 2017; 76:863.</a></li><li><a class="nounderline abstract_t">Arya V, Bansal M, Girard L, et al. Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review. Case Rep Dermatol 2010; 2:156.</a></li><li><a class="nounderline abstract_t">Burnett CT, Kouba DJ. Imiquimod-induced depigmentation: report of two cases and review of the literature. Dermatol Surg 2012; 38:1872.</a></li><li><a class="nounderline abstract_t">Li W, Xin H, Ge L, et al. Induction of vitiligo after imiquimod treatment of condylomata acuminata. BMC Infect Dis 2014; 14:329.</a></li><li><a class="nounderline abstract_t">Ghasri P, Gattu S, Saedi N, Ganesan AK. Chemical leukoderma after the application of a transdermal methylphenidate patch. J Am Acad Dermatol 2012; 66:e237.</a></li><li><a class="nounderline abstract_t">Weyant GW, Chung CG, Helm KF. Halo nevus: review of the literature and clinicopathologic findings. Int J Dermatol 2015; 54:e433.</a></li><li><a class="nounderline abstract_t">Botella-Estrada R, Kutzner H. Study of the immunophenotype of the inflammatory cells in melanomas with regression and halo nevi. Am J Dermatopathol 2015; 37:376.</a></li><li><a class="nounderline abstract_t">Quaglino P, Marenco F, Osella-Abate S, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol 2010; 21:409.</a></li><li><a class="nounderline abstract_t">Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996; 19:81.</a></li><li><a class="nounderline abstract_t">Yang Y, Lin X, Fu W, et al. An approach to the correlation between vitiligo and autoimmune thyroiditis in Chinese children. Clin Exp Dermatol 2010; 35:706.</a></li><li><a class="nounderline abstract_t">Boasberg PD, Hoon DS, Piro LD, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126:2658.</a></li><li><a class="nounderline abstract_t">Hartmann A, Bedenk C, Keikavoussi P, et al. Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges 2008; 6:1053.</a></li><li><a class="nounderline abstract_t">Guida M, Strippoli S, Maule M, et al. Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. ESMO Open 2021; 6:100064.</a></li><li><a class="nounderline abstract_t">Naveh HP, Rao UN, Butterfield LH. Melanoma-associated leukoderma - immunology in black and white? Pigment Cell Melanoma Res 2013; 26:796.</a></li><li><a class="nounderline abstract_t">Boissy RE, Manga P. On the etiology of contact/occupational vitiligo. Pigment Cell Res 2004; 17:208.</a></li><li><a class="nounderline abstract_t">Westerhof W, d'Ischia M. Vitiligo puzzle: the pieces fall in place. Pigment Cell Res 2007; 20:345.</a></li><li><a class="nounderline abstract_t">Vachiramon V, Thadanipon K. Postinflammatory hypopigmentation. Clin Exp Dermatol 2011; 36:708.</a></li><li><a class="nounderline abstract_t">Grimes PE, Bhawan J, Kim J, et al. Laser resurfacing-induced hypopigmentation: histologic alterations and repigmentation with topical photochemotherapy. Dermatol Surg 2001; 27:515.</a></li><li><a class="nounderline abstract_t">In SI, Yi SW, Kang HY, et al. Clinical and histopathological characteristics of pityriasis alba. Clin Exp Dermatol 2009; 34:591.</a></li><li><a class="nounderline abstract_t">Miazek N, Michalek I, Pawlowska-Kisiel M, et al. Pityriasis Alba--Common Disease, Enigmatic Entity: Up-to-Date Review of the Literature. Pediatr Dermatol 2015; 32:786.</a></li><li><a class="nounderline abstract_t">Blessmann Weber M, Sponchiado de Avila LG, Albaneze R, et al. Pityriasis alba: a study of pathogenic factors. J Eur Acad Dermatol Venereol 2002; 16:463.</a></li><li><a class="nounderline abstract_t">Rigopoulos D, Gregoriou S, Charissi C, et al. Tacrolimus ointment 0.1% in pityriasis alba: an open-label, randomized, placebo-controlled study. Br J Dermatol 2006; 155:152.</a></li><li><a class="nounderline abstract_t">Al-Mutairi N, Hadad AA. Efficacy of 308-nm xenon chloride excimer laser in pityriasis alba. Dermatol Surg 2012; 38:604.</a></li><li><a class="nounderline abstract_t">Sanchez M, Haimovic A, Prystowsky S. Sarcoidosis. Dermatol Clin 2015; 33:389.</a></li><li><a class="nounderline abstract_t">Boulos S, Vaid R, Aladily TN, et al. Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: a case series of 34 patients. J Am Acad Dermatol 2014; 71:1117.</a></li><li><a class="nounderline abstract_t">Furlan FC, Sanches JA. Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology. An Bras Dermatol 2013; 88:954.</a></li><li><a class="nounderline abstract_t">Tolkachjov SN, Comfere NI. Hypopigmented mycosis fungoides: a clinical mimicker of vitiligo. J Drugs Dermatol 2015; 14:193.</a></li><li><a class="nounderline abstract_t">Ngo JT, Trotter MJ, Haber RM. Juvenile-onset hypopigmented mycosis fungoides mimicking vitiligo. J Cutan Med Surg 2009; 13:230.</a></li><li><a class="nounderline abstract_t">Lane TN, Parker SS. Pityriasis lichenoides chronica in black patients. Cutis 2010; 85:125.</a></li><li><a class="nounderline abstract_t">Gupta AK, Batra R, Bluhm R, et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol 2004; 51:785.</a></li><li><a class="nounderline abstract_t">Crespo-Erchiga V, Florencio VD. Malassezia yeasts and pityriasis versicolor. Curr Opin Infect Dis 2006; 19:139.</a></li><li><a class="nounderline abstract_t">Schwartz RA. Superficial fungal infections. Lancet 2004; 364:1173.</a></li><li><a class="nounderline abstract_t">Ramos-e-Silva M, Rebello PF. Leprosy. Recognition and treatment. Am J Clin Dermatol 2001; 2:203.</a></li><li><a class="nounderline abstract_t">Talhari C, Talhari S, Penna GO. Clinical aspects of leprosy. Clin Dermatol 2015; 33:26.</a></li><li><a class="nounderline abstract_t">Farnsworth N, Rosen T. Endemic treponematosis: review and update. Clin Dermatol 2006; 24:181.</a></li><li><a class="nounderline abstract_t">Giacani L, Lukehart SA. The endemic treponematoses. Clin Microbiol Rev 2014; 27:89.</a></li><li><a class="nounderline abstract_t">Miranda MF, Bittencourt Mde J, Lopes Ida C, Cumino Sdo S. Leucoderma syphiliticum: a rare expression of the secondary stage diagnosed by histopathology. An Bras Dermatol 2010; 85:512.</a></li><li><a class="nounderline abstract_t">Kim SK, Kang HY, Lee ES, Kim YC. Clinical and histopathologic characteristics of nevus depigmentosus. J Am Acad Dermatol 2006; 55:423.</a></li><li><a class="nounderline abstract_t">Lee HS, Chun YS, Hann SK. Nevus depigmentosus: clinical features and histopathologic characteristics in 67 patients. J Am Acad Dermatol 1999; 40:21.</a></li><li><a class="nounderline abstract_t">Mountcastle EA, Diestelmeier MR, Lupton GP. Nevus anemicus. J Am Acad Dermatol 1986; 14:628.</a></li><li><a class="nounderline abstract_t">Greaves MW, Birkett D, Johnson C. Nevus anemicus: a unique catecholamine-dependent nevus. Arch Dermatol 1970; 102:172.</a></li><li><a class="nounderline abstract_t">Hernández-Martín A, García-Martínez FJ, Duat A, et al. Nevus anemicus: a distinctive cutaneous finding in neurofibromatosis type 1. Pediatr Dermatol 2015; 32:342.</a></li><li><a class="nounderline abstract_t">Sachs C, Lipsker D. Nevus Anemicus and Bier Spots in Tuberous Sclerosis Complex. JAMA Dermatol 2016; 152:217.</a></li><li><a class="nounderline abstract_t">Vaassen P, Rosenbaum T. Nevus Anemicus As an Additional Diagnostic Marker of Neurofibromatosis Type 1 in Childhood. Neuropediatrics 2016; 47:190.</a></li><li><a class="nounderline abstract_t">Kluger N, Bessis D. Bier's spots. J Eur Acad Dermatol Venereol 2019; 33:e78.</a></li><li><a class="nounderline abstract_t">Mahajan VK, Khatri G, Singh R, et al. Bier spots: An uncommon cause of mottled skin. Indian Dermatol Online J 2015; 6:128.</a></li><li><a class="nounderline abstract_t">He A, Kwatra SG, Kim N, Braunstein I. Bier spots: a benign vascular anomaly. BMJ Case Rep 2016; 2016.</a></li><li><a class="nounderline abstract_t">Fan YM, Yang YP, Li W, Li SF. Bier spots: six case reports. J Am Acad Dermatol 2009; 61:e11.</a></li><li><a class="nounderline abstract_t">Lin HC, Chen CH, Su HY. Bier spots on legs associated with deep vein thrombosis during pregnancy. Taiwan J Obstet Gynecol 2015; 54:102.</a></li><li><a class="nounderline abstract_t">Dean SM, Zirwas M. Bier spots are an under-recognized cutaneous manifestation of lower extremity lymphedema: a case series and brief review of the literature. Ann Vasc Surg 2014; 28:1935.e13.</a></li><li><a class="nounderline abstract_t">Bessis D, Jeziorski É, Rigau V, et al. Bier anaemic spots, cyanosis with urticaria-like eruption (BASCULE) syndrome: a new entity? Br J Dermatol 2016; 175:218.</a></li><li><a class="nounderline abstract_t">Bessis D, Dereure O, Rivire S, et al. Diffuse Bier white spots revealing cryoglobulinaemia. Br J Dermatol 2002; 146:921.</a></li><li><a class="nounderline abstract_t">Liu RC, Consuegra G, Chou S, Fernandez Peñas P. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. Clin Exp Dermatol 2019; 44:643.</a></li><li><a class="nounderline abstract_t">Shin MK, Jeong KH, Oh IH, et al. Clinical features of idiopathic guttate hypomelanosis in 646 subjects and association with other aspects of photoaging. Int J Dermatol 2011; 50:798.</a></li><li><a class="nounderline abstract_t">Falabella R, Escobar C, Giraldo N, et al. On the pathogenesis of idiopathic guttate hypomelanosis. J Am Acad Dermatol 1987; 16:35.</a></li><li><a class="nounderline abstract_t">Whitehead WJ, Moyer DG, Vander Ploeg DE. Idiopathic guttate hypomelanosis. Arch Dermatol 1966; 94:279.</a></li><li><a class="nounderline abstract_t">Cummings KI, Cottel WI. Idiopathic guttate hypomelanosis. Arch Dermatol 1966; 93:184.</a></li><li><a class="nounderline abstract_t">Ortonne JP, Perrot H. Idiopathic guttate hypomelanosis. Ultrastructural study. Arch Dermatol 1980; 116:664.</a></li><li><a class="nounderline abstract_t">Kim SK, Kim EH, Kang HY, et al. Comprehensive understanding of idiopathic guttate hypomelanosis: clinical and histopathological correlation. Int J Dermatol 2010; 49:162.</a></li><li><a class="nounderline abstract_t">Joshi R. Skip areas of retained melanin: a clue to the histopathological diagnosis of idiopathic guttate hypomelanosis. Indian J Dermatol 2014; 59:571.</a></li><li><a class="nounderline abstract_t">Kakepis M, Havaki S, Katoulis A, et al. Idiopathic guttate hypomelanosis: an electron microscopy study. J Eur Acad Dermatol Venereol 2015; 29:1435.</a></li><li><a class="nounderline abstract_t">Asawanonda P, Sutthipong T, Prejawai N. Pimecrolimus for idiopathic guttate hypomelanosis. J Drugs Dermatol 2010; 9:238.</a></li><li><a class="nounderline abstract_t">Rerknimitr P, Disphanurat W, Achariyakul M. Topical tacrolimus significantly promotes repigmentation in idiopathic guttate hypomelanosis: a double-blind, randomized, placebo-controlled study. J Eur Acad Dermatol Venereol 2013; 27:460.</a></li><li><a class="nounderline abstract_t">Chitvanich S, Rerknimitr P, Panchaprateep R, et al. Combination of non-ablative fractional photothermolysis and 0.1% tacrolimus ointment is efficacious for treating idiopathic guttate hypomelanosis. J Dermatolog Treat 2016; 27:456.</a></li><li><a class="nounderline abstract_t">Shin J, Kim M, Park SH, Oh SH. The effect of fractional carbon dioxide lasers on idiopathic guttate hypomelanosis: a preliminary study. J Eur Acad Dermatol Venereol 2013; 27:e243.</a></li><li><a class="nounderline abstract_t">Rerknimitr P, Chitvanich S, Pongprutthipan M, et al. Non-ablative fractional photothermolysis in treatment of idiopathic guttate hypomelanosis. J Eur Acad Dermatol Venereol 2015; 29:2238.</a></li><li><a class="nounderline abstract_t">Goldust M, Mohebbipour A, Mirmohammadi R. Treatment of idiopathic guttate hypomelanosis with fractional carbon dioxide lasers. J Cosmet Laser Ther 2013.</a></li><li><a class="nounderline abstract_t">Ravikiran SP, Sacchidanand S, Leelavathy B. Therapeutic wounding - 88% phenol in idiopathic guttate hypomelanosis. Indian Dermatol Online J 2014; 5:14.</a></li><li><a class="nounderline abstract_t">Arbache S, Hirata SH. Efficacy and Safety of 5-Fluorouracil Tattooing to Repigment Idiopathic Guttate Hypomelanosis: A Split-Body Randomized Trial. Dermatol Surg 2023; 49:603.</a></li><li><a class="nounderline abstract_t">Kumarasinghe SP. 3-5 second cryotherapy is effective in idiopathic guttate hypomelanosis. J Dermatol 2004; 31:437.</a></li><li><a class="nounderline abstract_t">Relyveld GN, Menke HE, Westerhof W. Progressive macular hypomelanosis: an overview. Am J Clin Dermatol 2007; 8:13.</a></li><li><a class="nounderline abstract_t">Westerhof W, Relyveld GN, Kingswijk MM, et al. Propionibacterium acnes and the pathogenesis of progressive macular hypomelanosis. Arch Dermatol 2004; 140:210.</a></li><li><a class="nounderline abstract_t">de Morais Cavalcanti SM, de França ER, Magalhães M, et al. A quantitative analysis of Propionibacterium acnes in lesional and non-lesional skin of patients with progressive macular hypomelanosis by real-time polymerase chain reaction. Braz J Microbiol 2011; 42:423.</a></li><li><a class="nounderline abstract_t">Relyveld GN, Westerhof W, Woudenberg J, et al. Progressive macular hypomelanosis is associated with a putative Propionibacterium species. J Invest Dermatol 2010; 130:1182.</a></li><li><a class="nounderline abstract_t">Guillet G, Helenon R, Gauthier Y, et al. Progressive macular hypomelanosis of the trunk: primary acquired hypopigmentation. J Cutan Pathol 1988; 15:286.</a></li><li><a class="nounderline abstract_t">Relyveld GN, Dingemans KP, Menke HE, et al. Ultrastructural findings in progressive macular hypomelanosis indicate decreased melanin production. J Eur Acad Dermatol Venereol 2008; 22:568.</a></li><li><a class="nounderline abstract_t">Wu XG, Xu AE, Song XZ, et al. Clinical, pathologic, and ultrastructural studies of progressive macular hypomelanosis. Int J Dermatol 2010; 49:1127.</a></li><li><a class="nounderline abstract_t">Kim MB, Kim GW, Cho HH, et al. Narrowband UVB treatment of progressive macular hypomelanosis. J Am Acad Dermatol 2012; 66:598.</a></li><li><a class="nounderline abstract_t">Relyveld GN, Kingswijk MM, Reitsma JB, et al. Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol 2006; 55:836.</a></li><li><a class="nounderline abstract_t">Sim JH, Lee DJ, Lee JS, Kim YC. Comparison of the clinical efficacy of NBUVB and NBUVB with benzoyl peroxide/clindamycin in progressive macular hypomelanosis. J Eur Acad Dermatol Venereol 2011; 25:1318.</a></li><li><a class="nounderline abstract_t">Santos JB, Almeida OL, Silva LM, Barreto ER. Efficacy of topical combination of benzoyl peroxide 5% and clindamycin 1% for the treatment of progressive macular hypomelanosis: a randomized, doubleblind, placebo-controlled trial. An Bras Dermatol 2011; 86:50.</a></li><li><a class="nounderline abstract_t">Falabella R, Escobar CE, Carrascal E, Arroyave JA. Leukoderma punctata. J Am Acad Dermatol 1988; 18:485.</a></li><li><a class="nounderline abstract_t">Fernandes NC, Pina JC. Leukoderma punctata following topical PUVAsol treatment. An Bras Dermatol 2010; 85:571.</a></li><li><a class="nounderline abstract_t">Dogra S, Jain R, Parsad D, Handa S. Leukoderma punctatum following systemic PUVA therapy. Int J Dermatol 2002; 41:922.</a></li><li><a class="nounderline abstract_t">Park JH, Lee MH. Case of leukoderma punctata after topical PUVA treatment. Int J Dermatol 2004; 43:138.</a></li><li><a class="nounderline abstract_t">McKenzie CA, Wakamatsu K, Hanchard NA, et al. Childhood malnutrition is associated with a reduction in the total melanin content of scalp hair. Br J Nutr 2007; 98:159.</a></li><li class="breakAll">Friedman PS. Metabolic, nutritional, and endocrine disorders. In: The Pigmentary System: Physiology and Pathophysiology, Nordlund JJ, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing, 2006. p.664.</li><li><a class="nounderline abstract_t">Brooks VE, Richards R. Depigmentation in Cushing's syndrome. Arch Intern Med 1966; 117:677.</a></li></ol></div><div id="topicVersionRevision">Topic 103736 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lapeere H, Boone B, De Schepper S, et al. Hypomelanoses and hypermelanoses. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith L, Katz SI, Gilchrest BA, et al (Eds), McGraw-Hill Medical, 2012. p.804.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456378" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Approach to hypopigmentation disorders in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20107718" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A practical classification of childhood hypopigmentation disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30236516" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Acquired disorders with depigmentation: A systematic approach to vitiliginoid conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30236514" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Acquired disorders with hypopigmentation: A clinical approach to diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17642589" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Wood's lamp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18782317" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chemical leucoderma: a clinico-aetiological study of 864 cases in the perspective of a developing country.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21063518" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chemical leukoderma: what's new on etiopathological and clinical aspects?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3288388" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chemical and pharmacologic agents that cause hyperpigmentation or hypopigmentation of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25000236" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Colors and contact dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14757713" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Environmental effects and skin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22630581" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Linear rays of hypopigmentation following intra-articular corticosteroid injection for post-traumatic degenerative joint disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25389730" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Eyelid cutaneous hypopigmentation after sub-tenon triamcinolone injection after retinal detachment repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24139363" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24467724" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20118061" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32454097" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Immune checkpoint inhibitor-related dermatologic adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28094061" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21076689" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Vitiligo at Injection Site of PEG-IFN-α2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22805097" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Imiquimod-induced depigmentation: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24928346" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Induction of vitiligo after imiquimod treatment of condylomata acuminata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22583724" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chemical leukoderma after the application of a transdermal methylphenidate patch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26146814" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Halo nevus: review of the literature and clinicopathologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25222195" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Study of the immunophenotype of the inflammatory cells in melanomas with regression and halo nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19622589" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8859727" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19874359" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : An approach to the correlation between vitiligo and autoimmune thyroiditis in Chinese children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16946711" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18479500" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33711672" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24010963" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Melanoma-associated leukoderma - immunology in black and white?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15140065" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : On the etiology of contact/occupational vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17850508" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vitiligo puzzle: the pieces fall in place.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21671990" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Postinflammatory hypopigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11442585" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Laser resurfacing-induced hypopigmentation: histologic alterations and repigmentation with topical photochemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19094127" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical and histopathological characteristics of pityriasis alba.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26477326" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pityriasis Alba--Common Disease, Enigmatic Entity: Up-to-Date Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12428838" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pityriasis alba: a study of pathogenic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16792767" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Tacrolimus ointment 0.1% in pityriasis alba: an open-label, randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22122662" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy of 308-nm xenon chloride excimer laser in pityriasis alba.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26143421" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25264240" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: a case series of 34 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24474105" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25689815" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hypopigmented mycosis fungoides: a clinical mimicker of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706233" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Juvenile-onset hypopigmented mycosis fungoides mimicking vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20408509" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pityriasis lichenoides chronica in black patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15523360" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Skin diseases associated with Malassezia species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16514338" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Malassezia yeasts and pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15451228" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Superficial fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11705247" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Leprosy. Recognition and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25432808" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical aspects of leprosy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16714199" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Endemic treponematosis: review and update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24396138" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The endemic treponematoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20944911" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Leucoderma syphiliticum: a rare expression of the secondary stage diagnosed by histopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908347" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical and histopathologic characteristics of nevus depigmentosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922008" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Nevus depigmentosus: clinical features and histopathologic characteristics in 67 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3007588" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Nevus anemicus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5430312" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Nevus anemicus: a unique catecholamine-dependent nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25690591" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Nevus anemicus: a distinctive cutaneous finding in neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26580703" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Nevus Anemicus and Bier Spots in Tuberous Sclerosis Complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27019377" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Nevus Anemicus As an Additional Diagnostic Marker of Neurofibromatosis Type 1 in Childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30160813" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bier's spots.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25821739" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Bier spots: An uncommon cause of mottled skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26912771" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Bier spots: a benign vascular anomaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19700009" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Bier spots: six case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25675934" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Bier spots on legs associated with deep vein thrombosis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25017780" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Bier spots are an under-recognized cutaneous manifestation of lower extremity lymphedema: a case series and brief review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27016170" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Bier anaemic spots, cyanosis with urticaria-like eruption (BASCULE) syndrome: a new entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12000400" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Diffuse Bier white spots revealing cryoglobulinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30618056" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21699514" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinical features of idiopathic guttate hypomelanosis in 646 subjects and association with other aspects of photoaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3805391" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : On the pathogenesis of idiopathic guttate hypomelanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4951808" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Idiopathic guttate hypomelanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5904027" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Idiopathic guttate hypomelanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7377803" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Idiopathic guttate hypomelanosis. Ultrastructural study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20465639" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Comprehensive understanding of idiopathic guttate hypomelanosis: clinical and histopathological correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25484386" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Skip areas of retained melanin: a clue to the histopathological diagnosis of idiopathic guttate hypomelanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25088925" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Idiopathic guttate hypomelanosis: an electron microscopy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20232585" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pimecrolimus for idiopathic guttate hypomelanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22324720" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Topical tacrolimus significantly promotes repigmentation in idiopathic guttate hypomelanosis: a double-blind, randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26864301" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Combination of non-ablative fractional photothermolysis and 0.1% tacrolimus ointment is efficacious for treating idiopathic guttate hypomelanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22646755" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The effect of fractional carbon dioxide lasers on idiopathic guttate hypomelanosis: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25303024" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Non-ablative fractional photothermolysis in treatment of idiopathic guttate hypomelanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23656568" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Treatment of idiopathic guttate hypomelanosis with fractional carbon dioxide lasers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24616848" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Therapeutic wounding - 88% phenol in idiopathic guttate hypomelanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37011024" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Efficacy and Safety of 5-Fluorouracil Tattooing to Repigment Idiopathic Guttate Hypomelanosis: A Split-Body Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187317" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : 3-5 second cryotherapy is effective in idiopathic guttate hypomelanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17298102" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Progressive macular hypomelanosis: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14967796" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Propionibacterium acnes and the pathogenesis of progressive macular hypomelanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24031649" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A quantitative analysis of Propionibacterium acnes in lesional and non-lesional skin of patients with progressive macular hypomelanosis by real-time polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20043017" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Progressive macular hypomelanosis is associated with a putative Propionibacterium species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3209765" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Progressive macular hypomelanosis of the trunk: primary acquired hypopigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18266692" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Ultrastructural findings in progressive macular hypomelanosis indicate decreased melanin production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20931684" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Clinical, pathologic, and ultrastructural studies of progressive macular hypomelanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22005073" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Narrowband UVB treatment of progressive macular hypomelanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17052490" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349111" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Comparison of the clinical efficacy of NBUVB and NBUVB with benzoyl peroxide/clindamycin in progressive macular hypomelanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21437522" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Efficacy of topical combination of benzoyl peroxide 5% and clindamycin 1% for the treatment of progressive macular hypomelanosis: a randomized, doubleblind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3351013" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Leukoderma punctata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20944925" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Leukoderma punctata following topical PUVAsol treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12492990" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Leukoderma punctatum following systemic PUVA therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15125506" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Case of leukoderma punctata after topical PUVA treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17381963" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Childhood malnutrition is associated with a reduction in the total melanin content of scalp hair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17381963" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Childhood malnutrition is associated with a reduction in the total melanin content of scalp hair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5933558" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Depigmentation in Cushing's syndrome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
